Abstracts tagged "Inflammation"

Abstract Number: 0653 • ACR Convergence 2020
Nutrient Content of Gout Flare Trigger Foods
Tanya Major¹, Ruth Topless¹, Elsa Sanchez-Lopez², Jennie Harré Hindmarsh³, Lisa Stamp⁴, Nicola Dalbeth⁵, Monica Guma⁶, Robert Terkeltaub⁷ and Tony Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of California San Diego, San Diego, CA, ³Ngāti Porou Hauora, Te Puia Springs, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of California San Diego, La Jolla, CA, ⁷VA/UCSD, San Diego, CA
Background/Purpose: A wide variety of foods are reported by patients to be triggers of gout flares. Some of these foods have been associated with serum…
Abstract Number: 0889 • ACR Convergence 2020
Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies
Christopher Ritchlin¹, Alan Kivitz², Peter Nash³, Renato Calheiros⁴, Xiangyi Meng⁵, Corine Gaillez⁶, Bruce Kirkham⁷ and Iain McInnes⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) can progress quickly and lead to irreversible damage within 2 years of initial assessment if not treated.1 Secukinumab (SEC), a selective…
Abstract Number: 1217 • ACR Convergence 2020
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells
Yuya Fujita¹, Naoki Matsuoka¹, Makiko Furuya-Yashiro², Jumpei Temmoku², Yuki Kuroiwa³, Masaru Tanaka⁴, Tomoyuki Asano², Shuzo Sato⁵, Haruki Matsumoto², Hiroshi Watanabe², Hideko Kuzuru⁶, Hiroshi Yatsuhashi⁷, Atsushi Kawakami⁸ and Kiyoshi Migita⁹, ¹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan, ²Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ³Eli Lilly Japan K.K., Tokyo, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ⁶NHO Nagasaki Medical Center, Clinical Research Center, Omura, Japan, ⁷NHO Nagasaki Medical Center, Clinical Research Center, Omura, Nagasaki, Japan, ⁸Nagasaki University Graduate School of Biomedical Sciences, Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki, Nagasaki, Japan, ⁹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan
Background/Purpose: Janus kinase (JAK) family is comprised of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). JAKs form homo- or hetero-complexes, the combination of which…
Abstract Number: 1563 • ACR Convergence 2020
High Impact Sports Leads to Inflammatory Responses at Entheseal Sites Results of the BEAT Study (Badminton Enthesitis Arthrosonography Study)
David Simon¹, Arnd Kleyer¹, Koray Tascilar¹, Sara Bayat², Johannes Knitza³, Larissa Valor-Mendez⁴, Marina Schweiger⁵, Georg Schett⁶ and Axel Hueber⁷, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Internal Medicine 3, Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Bayern, Germany, ⁵Department of Internal Medicine 3, Rheumatology and Immunology, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁷Sektion Rheumatologie, Sozialstiftung Bamberg, Bamberg, Germany
Background/Purpose: Biomechanical stress triggers entheseal inflammation in psoriatic disease [1,2]. However, there is only limited data on the impact of mechanical stress on entheseal sites…
Abstract Number: 1948 • ACR Convergence 2020
Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes
Tadashi Hosoya¹, Nikunj Shukla², Yuya Fujita³, Shiyin Yao⁴, Fitzgerald Lao⁴, Hiroyuki Baba¹, Shinsuke Yasuda⁵, Howard Cottam⁴, Dennis Carson⁴, Tomoko Hayashi⁴ and Mary Corr⁶, ¹Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ²Moores Cancer Center, University of California San Diego, San Diego, CA, ³Department of Medicine, University of California San Diego, San Diego, CA, ⁴Moores Cancer Center, University of California San Diego, San Diego, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁶Department of Medicine, University of California San Diego, San Diego
Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…
Abstract Number: 0350 • ACR Convergence 2020
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Atul Deodhar¹, Philip Mease², Paula Machado³, Effie Pournara⁴, Xiangyi Meng³, Vibeke Strand⁵ and Marina Magrey⁶, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease involving the sacroiliac joints and spine and associated with pain, stiffness, and disability.1 A previous analysis…
Abstract Number: 0693 • ACR Convergence 2020
Effect of Physical Activity on Cartilage Degradation and Inflammation in Individuals with Lumbar Spinal Stenosis
Gustavo Almeida¹, Samannaaz Khoja², Lauren Terhorst³, Gwendolyn Sowa⁴, Sara Piva² and Michael Schneider², ¹Department of Physical Therapy, UT HEALTH SAN ANTONIO, San Antonio, TX, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Guidelines recommend 150 minutes a week in moderate-intensity physical activity (MPA) to improve health in individuals with chronic disease such as those with lumbar…
Abstract Number: 0945 • ACR Convergence 2020
Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun², Lena Tanaka², James Kuchenbecker², Tomas Mustelin¹ and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Sensitivity to ultraviolet (UV) light affects up to 80% of SLE patients and can exacerbate systemic disease flares, including lupus nephritis (LN). Our findings…
Abstract Number: 1233 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Jonathan Kay¹, Amy Bock², Noriko Iikuni³, Wuyan Zhang⁴ and Daniel Alvarez⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Cambridge, MA, ³Pfizer, New York, NY, ⁴Pfizer, New York, ⁵Pfizer, Collegeville, PA
Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: PP03 • ACR Convergence 2020
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
Nancy Linn¹, Catherine Bammert², David Bammert³ and Michael Linn⁴, ¹Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, ²MD Anderson, Houston, TX, ³Relapsing Polychondritis Foundation, Houston, TX, ⁴Relapsing Polychondritis Foundation, New York, NY
Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
Abstract Number: 0366 • ACR Convergence 2020
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Philip Mease¹, Atul Deodhar², Renato Calheiros³, Xiangyi Meng⁴, Todd Fox⁵ and Xenofon Baraliakos⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Aesch, Switzerland, ⁶Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…
Abstract Number: 0700 • ACR Convergence 2020
Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Mandar Dave¹, Abul Islam², Akshat Parekh³, Jay Patel⁴, Arushi Chawla⁵ and Ashok Amin⁶, ¹Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, ²Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh, ³Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, ⁴Northeast Ohio Medical University, Rootstown, OH, ⁵Gujarat Forensic Science University, Gujarat, India, ⁶Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Human OA-affected cartilage does not show the cardinal signs of inflammation (redness and swelling with heat and pain—rubor et tumor cum calore et dolor) because…
Abstract Number: 0946 • ACR Convergence 2020
ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun² and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Systemic lupus erythematosus (SLE) patients have a prominent type I interferon (IFN-I) signature in both the lesional and non-lesional skin. We recently showed that…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].